Bold headline: Novo Nordisk eyes Wegovy vials as obesity-drug race heats up.
Novo Nordisk, listed on the NYSE as NVO, has disclosed plans to roll out Wegovy in vial form. The company stated that it is evaluating multiple presentation options for Wegovy, including vials, with some launches expected this year and others slated for the future. At present, Wegovy is available in both injectable formats and oral form.
This move follows a notable move by Eli Lilly, which first introduced vial options for the two lowest-dose versions of its weight-loss medication, Zepbound, in 2024. In 2024, Lilly also reduced prices for Zepbound vials and broadened the dose range available online.
The competition intensified in 2025 when Zepbound surpassed Wegovy in U.S. prescription counts, signaling a tougher period for Novo Nordisk in the high-stakes obesity-drug market. By pursuing vial presentations, Novo Nordisk aims to reclaim market share amid a rapidly evolving landscape.
Market reaction has been modestly negative on the news: Novo Nordisk’s stock slipped about 0.9% on Thursday, trading near $48, and it has declined roughly 5% for the year to date.
Discussion prompts: Do vial formats truly drive more prescriptions, or do patient preferences and payer dynamics play the larger role? How might differences in dosing, supply, and pricing shape the next chapter of this ongoing rivalry between Wegovy and Zepbound? Share your thoughts in the comments.
